Self-reported titration described in community sources: 0.25 mg 3x/week for week 1, then 0.5 mg 3x/week thereafter, with optional 8-week-on / 8-week-off cycling
GLP-1 plays a critical role in regulating blood sugar levels by stimulating insulin secretion from the pancreas after meals, slowing gastric emptying, and reducing appetite
[16] [17] Whether these risks apply to retatrutide specifically is not yet established, as the full long-term safety profile remains unknown pending Phase 3 data
GLP-1 medications do not directly cause pelvic floor dysfunction, but the straining associated with hard, dry stool can trigger or worsen existing coordination problems
GLP-1 and GIP are hormones that are released soon after you eat a meal Your body must carefully maintain the levels of sugar in your bloodstream within a narrow range
Future studies should focus on the long-term outcomes of retatrutide treatment, including its impact on obesity-related complications and quality of life